No Detail Found!

Frequency of Macroprolactin in Hyperprolactinemia.

Author(s)
Noreen Abbas Sherazi Department of Clinical Chemistry and Immunology, Chughtai Laboratory, Karachi, Pakistan
Mirza Zain Baig The Aga Khan University, Karachi, Pakistan
Aysha Habib Khan Department of Pathology and Laboratory Medicine, The Aga Khan University, Karachi, Pakistan
Abstract
Objective: To determine the frequency of Macroprolactin (MaPRL) in patients with increased total prolactin and its clinical and financial impact. Study Design: Cross-sectional study. Place and Duration of Study: Section of Clinical Chemistry, Department of Pathology and Laboratory Medicine, The Aga Khan University Hospital, Karachi, from March to May 2015. Methodology: Patients with high total prolactin were screened by polyethylene glycol (PEG) precipitation for determination of MaPRL. Clinical history, imaging work-ups, and cost incurred in further investigations were collected by telephonic interview after verbal consent. Patients were stratified into true hyperprolactinemia and macroprolactinemia after PEG treatment, based on monomeric prolactin levels. Medical records of cases registered with AKUH were reviewed to confirm the diagnosis. Results: Two hundred and thirty-nine patients were identified with high prolactin levels. Macroprolactinemia was identified in 145 (60.7%) and true hyperprolactinemia in 94 (39.3%) patients. Galactorrhea was significantly more in true hyperprolactinemic females (p=0.022), followed by visual disturbances (p=0.01) and headache (p=0.006). Moreover, as majority of population were females, the clinical features in the macroprolactinemia group as compared to true hyperprolactinemic group were mostly related to non-pituitary causes like drug intake [42.5% (54) vs. 37% (30)], heat intolerance due to thyroidal illness [41.7% (53) vs. 38.3% (31)] and surgery [26.8% (34) vs 22.2% (18)] in females. Further radiological workup (MRI, CT) were conducted in 35 (37.2%) patients with true hyperprolactinemia. Twenty-one (60%) of the patients were confirmed to have pituitary adenomas. In eight (5.5%) patients with MaPRL, only one had pituitary microadenoma on radiological workup. Total cost impact on the basis of investigations, was significantly higher in the group undergone imaging, despite 7 out of 8 individuals found to have normal imaging results. The median total cost in true hyperprolactinemic group undergone imaging was Rs. 4370 (IQR=2412.5, 22850) as compared to macroprolactinemic groups; Rs. 3,250 (IQR=2150, 4278). There was significant difference in the cost burden of both the groups (p <0.001). Conclusion: High frequency of MaPRL was identified in patients with hyperprolactinemia. Screening with PEG precipitation in hyperprolactinemic sera is simple and cost-effective.
Publication Details
Page(s) 93-97
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 28, Issue: 2, Year: 2018

Request the full text from PASTIC

References
Beda-MalugaK,PisarekH,KomorowskiJ,PawlikowskiM,SwietoslawskiJ,WinczykK, 2011.The detection of macroprolactin by precipitation and ultrafiltration methods,Endokrynol Pol 62 529 -36
SmithTP,Fahie-WilsonMN, 2010.Reporting of post-PEG prolactin concentrations: time to change,Clin Chem 56 484 -5
KavanaghL,McKennaTJ,Fahie-WilsonMN,GibneyJ,SmithTP, 2006.Specificity and clinical utility of methods for the detection of macroprolactin,Clin Chem 52 1366 -72
RichaV,RahulG,SarikaA, .Macroprolactin; a frequent cause of misdiagnosed hyperprolactinemia in clinical practice,J Reprod Infertil 11 161 -7
CasanuevaFF,MolitchME,SchlechteJA,AbsR,BonertV,BronsteinMD, 2006.Guidelines of the pituitary society for the diagnosis and management of prolactinomas,Clin Endocrinol (Oxf) 65 265 -73
SulimanAM,SmithTP,GibneyJ,McKennaTJ, 2003.Frequent misdiagnosis and mismanagement of hyperprolactinemic patients before the introduction of macroprolactin screening: application of a new strict laboratory definition of macroprolactinemia,Clin Chem 49 1504 -9
BeltranL,Fahie-WilsonMN,McKennaTJ,SmithTP, 2008.Serum total prolactin and monomeric prolactin reference intervals determined by precipitation with polyethylene glycol: evaluation and validation on common immunoassay platforms,Clin Chem 54 1673 -81
CavacoB,PrazeresS,SantosMA,SobrinhoLG,LeiteV, 1999.Hyperprolactinemia due to big, big prolactin is differently detected by commercially available immunoassays,J Endocrinol Invest 22 203 -8
Fahie-WilsonM,SmithTP, 2013.Determination of prolactin: the macroprolactin problem,Best Pract Res Clin Endocrinol Metab 27 725 -42
HauacheOM,RochaAJ,MaiaAC,MacielRM,VieiraJG, 2002.Screening for macroprolactinaemia and pituitary imaging studies,Clin Endocrinol (Oxf) 57 327 -31
CavacoB,LeiteV,SantosMA,ArranhadoE,SobrinhoLG, 1995.Some forms of big, big prolactin behave as a complex of monomeric prolactin with an immunoglobulin G in patients with macroprolactinemia or prolactinoma,J Clin Endocrinol Metab 80 2342 -6
MolitchME,RussellEJ, 1990.The pituitary "incidentaloma",Ann Intern Med 112 925 -31
de SoarezPC,SouzaSC,VieiraJG,FerrazMB, 2009.The effect of identifying macroprolactinemia on health-care utilization and costs in patients with elevated serum prolactin levels,Value Health 12 930 -4
GibneyJ,SmithTP,McKennaTJ, 2005.The impact on clinical practice of routine screening for macroprolactin,J Clin Endocrinol Metab 90 3927 -32
FredaPU,BeckersAM,KatznelsonL,MolitchME,MontoriVM,PostKD, 2011.Pituitary incidentaloma: an endocrine society clinical practice guideline,J Clin Endocrinol Metab 96 894 -904
0

Citations

0

Downloads

139

Views